ticlopidine has been researched along with 2019 Novel Coronavirus Disease in 1 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anchidin, OI | 1 |
| Rosianu, SH | 1 |
| Nemes, A | 1 |
| Aldica, M | 1 |
| Blendea, D | 1 |
| Molnar, A | 1 |
| Moldovan, H | 1 |
| Pop, D | 1 |
1 other study available for ticlopidine and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
The Effectiveness of Antiplatelet Therapy and the Factors Influencing It in Patients with Acute Coronary Syndrome before and during the COVID-19 Pandemic.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; COVID-19; Drug Therapy, Combination; Human | 2022 |